Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients.

Sanai N, Li J, Boerner J, Stark K, Wu J, Kim S, Derogatis A, Mehta S, Dhruv HD, Heilbrun LK, Berens ME, LoRusso PM.

Clin Cancer Res. 2018 Aug 15;24(16):3820-3828. doi: 10.1158/1078-0432.CCR-17-3348. Epub 2018 May 24.

PMID:
29798906
2.

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).

Gadgeel SM, Pennell NA, Fidler MJ, Halmos B, Bonomi P, Stevenson J, Schneider B, Sukari A, Ventimiglia J, Chen W, Galasso C, Wozniak A, Boerner J, Kalemkerian GP.

J Thorac Oncol. 2018 Jul 17. pii: S1556-0864(18)30600-2. doi: 10.1016/j.jtho.2018.05.002. [Epub ahead of print]

PMID:
29775808
3.

Heterogeneity of Human Breast Stem and Progenitor Cells as Revealed by Transcriptional Profiling.

Colacino JA, Azizi E, Brooks MD, Harouaka R, Fouladdel S, McDermott SP, Lee M, Hill D, Madden J, Boerner J, Cote ML, Sartor MA, Rozek LS, Wicha MS.

Stem Cell Reports. 2018 May 8;10(5):1596-1609. doi: 10.1016/j.stemcr.2018.03.001. Epub 2018 Mar 29.

4.

Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.

Thakur MK, Heilbrun L, Dobson K, Boerner J, Stark K, Li J, Smith D, Heath E, Fontana J, Vaishampayan U.

Clin Genitourin Cancer. 2018 Jun;16(3):e695-e703. doi: 10.1016/j.clgc.2018.01.019. Epub 2018 Feb 13.

PMID:
29534939
5.

Noisy vestibular stimulation improves vestibulospinal function in patients with bilateral vestibulopathy.

Schniepp R, Boerner JC, Decker J, Jahn K, Brandt T, Wuehr M.

J Neurol. 2018 Mar 5. doi: 10.1007/s00415-018-8814-y. [Epub ahead of print]

PMID:
29508134
6.

Stochastic resonance in the human vestibular system - Noise-induced facilitation of vestibulospinal reflexes.

Wuehr M, Boerner JC, Pradhan C, Decker J, Jahn K, Brandt T, Schniepp R.

Brain Stimul. 2018 Mar - Apr;11(2):261-263. doi: 10.1016/j.brs.2017.10.016.

PMID:
29100928
7.

Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity.

Bao B, Mitrea C, Wijesinghe P, Marchetti L, Girsch E, Farr RL, Boerner JL, Mohammad R, Dyson G, Terlecky SR, Bollig-Fischer A.

Sci Rep. 2017 Mar 10;7:44125. doi: 10.1038/srep44125.

8.

Axon Termination, Pruning, and Synaptogenesis in the Giant Fiber System of Drosophila melanogaster Is Promoted by Highwire.

Borgen M, Rowland K, Boerner J, Lloyd B, Khan A, Murphey R.

Genetics. 2017 Mar;205(3):1229-1245. doi: 10.1534/genetics.116.197343. Epub 2017 Jan 18.

9.

Insulin-IGF signaling affects cell transformation in the BALB/c 3T3 cell model.

Poburski D, Leovsky C, Boerner JB, Szimmtenings L, Ristow M, Glei M, Thierbach R.

Sci Rep. 2016 Nov 16;6:37120. doi: 10.1038/srep37120.

10.

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.

Linklater ES, Tovar EA, Essenburg CJ, Turner L, Madaj Z, Winn ME, Melnik MK, Korkaya H, Maroun CR, Christensen JG, Steensma MR, Boerner JL, Graveel CR.

Oncotarget. 2016 Oct 25;7(43):69903-69915. doi: 10.18632/oncotarget.12065.

11.

Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer.

Zoratti GL, Tanabe LM, Hyland TE, Duhaime MJ, Colombo É, Leduc R, Marsault E, Johnson MD, Lin CY, Boerner J, Lang JE, List K.

Oncotarget. 2016 Sep 6;7(36):58162-58173. doi: 10.18632/oncotarget.11262.

12.

Time-resolved functional analysis of acute impairment of frataxin expression in an inducible cell model of Friedreich ataxia.

Poburski D, Boerner JB, Koenig M, Ristow M, Thierbach R.

Biol Open. 2016 May 15;5(5):654-61. doi: 10.1242/bio.017004.

13.

Epidermal Growth Factor Receptor Kinase Inhibitors Synergize with TCDD to Induce CYP1A1/1A2 in Human Breast Epithelial MCF10A Cells.

Joiakim A, Mathieu PA, Shelp C, Boerner J, Reiners JJ Jr.

Drug Metab Dispos. 2016 May;44(5):665-71. doi: 10.1124/dmd.115.066274. Epub 2016 Mar 7.

14.

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.

LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, Smith D, Pilat MJ, Zhang J, Tolaney SM, Cleary JM, Chen AP, Rubinstein L, Boerner JL, Bowditch A, Cai D, Bell T, Wolanski A, Marrero AM, Zhang Y, Ji J, Ferry-Galow K, Kinders RJ, Parchment RE, Shapiro GI.

Clin Cancer Res. 2016 Jul 1;22(13):3227-37. doi: 10.1158/1078-0432.CCR-15-0652. Epub 2016 Feb 3.

15.

Targeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling.

Zoratti GL, Tanabe LM, Varela FA, Murray AS, Bergum C, Colombo É, Lang JE, Molinolo AA, Leduc R, Marsault E, Boerner J, List K.

Nat Commun. 2015 Apr 15;6:6776. doi: 10.1038/ncomms7776.

16.

Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.

Boerner JL, Nechiporchik N, Mueller KL, Polin L, Heilbrun L, Boerner SA, Zoratti GL, Stark K, LoRusso PM, Burger A.

PLoS One. 2015 Mar 16;10(3):e0119614. doi: 10.1371/journal.pone.0119614. eCollection 2015.

17.

Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer.

Madden JM, Mueller KL, Bollig-Fischer A, Stemmer P, Mattingly RR, Boerner JL.

Breast Cancer Res Treat. 2014 Sep;147(2):283-93. doi: 10.1007/s10549-014-3102-8. Epub 2014 Aug 17.

18.

Regulation of the Src-PP2A interaction in tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.

Xu J, Xu Z, Zhou JY, Zhuang Z, Wang E, Boerner J, Wu GS.

J Biol Chem. 2013 Nov 15;288(46):33263-71. doi: 10.1074/jbc.M113.508093. Epub 2013 Oct 7.

19.

Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.

Kim EM, Mueller K, Gartner E, Boerner J.

J Surg Res. 2013 Nov;185(1):231-9. doi: 10.1016/j.jss.2013.06.041. Epub 2013 Jul 17.

PMID:
23899511
20.

The diagnosis and treatment of generalized anxiety disorder.

Bandelow B, Boerner J R, Kasper S, Linden M, Wittchen HU, Möller HJ.

Dtsch Arztebl Int. 2013 Apr;110(17):300-9; quiz 310. doi: 10.3238/arztebl.2013.0300. Epub 2013 Apr 26.

21.

Transsynaptic coordination of synaptic growth, function, and stability by the L1-type CAM Neuroglian.

Enneking EM, Kudumala SR, Moreno E, Stephan R, Boerner J, Godenschwege TA, Pielage J.

PLoS Biol. 2013;11(4):e1001537. doi: 10.1371/journal.pbio.1001537. Epub 2013 Apr 16.

22.

EGFR Tyrosine 845 Phosphorylation-Dependent Proliferation and Transformation of Breast Cancer Cells Require Activation of p38 MAPK.

Mueller KL, Powell K, Madden JM, Eblen ST, Boerner JL.

Transl Oncol. 2012 Oct;5(5):327-34. Epub 2012 Oct 1.

23.

Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer.

Hou J, Wu J, Dombkowski A, Zhang K, Holowatyj A, Boerner JL, Yang ZQ.

Am J Transl Res. 2012;4(3):247-56. Epub 2012 Jul 22.

24.
25.

A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells.

Giordano CR, Mueller KL, Terlecky LJ, Krentz KA, Bollig-Fischer A, Terlecky SR, Boerner JL.

Exp Cell Res. 2012 Oct 1;318(16):2014-21. doi: 10.1016/j.yexcr.2012.06.001. Epub 2012 Jun 8.

26.

Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells.

Irwin ME, Bohin N, Boerner JL.

Cancer Biol Ther. 2011 Oct 15;12(8):718-26. doi: 10.4161/cbt.12.8.16907. Epub 2011 Oct 15.

27.

Strong expression association between matriptase and its substrate prostasin in breast cancer.

Bergum C, Zoratti G, Boerner J, List K.

J Cell Physiol. 2012 Apr;227(4):1604-9. doi: 10.1002/jcp.22877.

PMID:
21678412
28.

Whole mount preparation of the adult Drosophila ventral nerve cord for giant fiber dye injection.

Boerner J, Godenschwege TA.

J Vis Exp. 2011 Jun 4;(52). pii: 3080. doi: 10.3791/3080.

29.

Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.

Irwin ME, Mueller KL, Bohin N, Ge Y, Boerner JL.

J Cell Physiol. 2011 Sep;226(9):2316-28. doi: 10.1002/jcp.22570.

30.

EGFR/Met association regulates EGFR TKI resistance in breast cancer.

Mueller KL, Yang ZQ, Haddad R, Ethier SP, Boerner JL.

J Mol Signal. 2010 Jul 12;5:8. doi: 10.1186/1750-2187-5-8.

31.

Application for the Drosophila ventral nerve cord standard in neuronal circuit reconstruction and in-depth analysis of mutant morphology.

Boerner J, Godenschwege TA.

J Neurogenet. 2010 Sep;24(3):158-67. doi: 10.3109/01677063.2010.489624.

32.

Average shape standard atlas for the adult Drosophila ventral nerve cord.

Boerner J, Duch C.

J Comp Neurol. 2010 Jul 1;518(13):2437-55. doi: 10.1002/cne.22346.

PMID:
20503421
33.

The Murray Springs Clovis site, Pleistocene extinction, and the question of extraterrestrial impact.

Haynes CV Jr, Boerner J, Domanik K, Lauretta D, Ballenger J, Goreva J.

Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4010-5. doi: 10.1073/pnas.0908191107. Epub 2010 Feb 16.

34.

Epidermal growth factor receptor translocation to the mitochondria: regulation and effect.

Demory ML, Boerner JL, Davidson R, Faust W, Miyake T, Lee I, Hüttemann M, Douglas R, Haddad G, Parsons SJ.

J Biol Chem. 2009 Dec 25;284(52):36592-604. doi: 10.1074/jbc.M109.000760. Epub 2009 Oct 19.

35.

RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia.

Edwards H, Xie C, LaFiura KM, Dombkowski AA, Buck SA, Boerner JL, Taub JW, Matherly LH, Ge Y.

Blood. 2009 Sep 24;114(13):2744-52. doi: 10.1182/blood-2008-09-179812. Epub 2009 Jul 28.

36.

Role of Src family kinases in acquired resistance to EGFR therapies in cancer.

Boerner JL.

Cancer Biol Ther. 2009 Apr;8(8):704-6. No abstract available.

PMID:
19417559
37.

Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.

Mueller KL, Hunter LA, Ethier SP, Boerner JL.

Cancer Res. 2008 May 1;68(9):3314-22. doi: 10.1158/0008-5472.CAN-08-0132.

38.

Activation of a nuclear factor kappaB/interleukin-1 positive feedback loop by amphiregulin in human breast cancer cells.

Streicher KL, Willmarth NE, Garcia J, Boerner JL, Dewey TG, Ethier SP.

Mol Cancer Res. 2007 Aug;5(8):847-61. Epub 2007 Aug 1.

39.

NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon.

Ma S, Boerner JE, TiongYip C, Weidmann B, Ryder NS, Cooreman MP, Lin K.

Antimicrob Agents Chemother. 2006 Sep;50(9):2976-82.

40.

Crystallization on confined engineered surfaces: a method to control crystal size and generate different polymorphs.

Lee AY, Lee IS, Dette SS, Boerner J, Myerson AS.

J Am Chem Soc. 2005 Nov 2;127(43):14982-3.

PMID:
16248610
41.

Transactivating agonists of the EGF receptor require Tyr 845 phosphorylation for induction of DNA synthesis.

Boerner JL, Biscardi JS, Silva CM, Parsons SJ.

Mol Carcinog. 2005 Dec;44(4):262-73.

PMID:
16167350
42.

Estrogen negatively regulates epidermal growth factor (EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptor-overexpressing breast cancer cells.

Boerner JL, Gibson MA, Fox EM, Posner ED, Parsons SJ, Silva CM, Shupnik MA.

Mol Endocrinol. 2005 Nov;19(11):2660-70. Epub 2005 Jun 23.

PMID:
15976008
43.

Allosteric effects of ligands and mutations on poliovirus RNA-dependent RNA polymerase.

Boerner JE, Lyle JM, Daijogo S, Semler BL, Schultz SC, Kirkegaard K, Richards OC.

J Virol. 2005 Jun;79(12):7803-11.

44.

Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer.

Rich T, Innominato PF, Boerner J, Mormont MC, Iacobelli S, Baron B, Jasmin C, Lévi F.

Clin Cancer Res. 2005 Mar 1;11(5):1757-64.

45.
46.

Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis.

Boerner JL, Danielsen AJ, Lovejoy CA, Wang Z, Juneja SC, Faupel-Badger JM, Darce JR, Maihle NJ.

Oncogene. 2003 Oct 2;22(43):6679-89.

PMID:
14555981
47.

Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm.

Boerner JL, Danielsen A, Maihle NJ.

Exp Cell Res. 2003 Mar 10;284(1):111-21. Review.

PMID:
12648470
48.

STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor.

Kloth MT, Laughlin KK, Biscardi JS, Boerner JL, Parsons SJ, Silva CM.

J Biol Chem. 2003 Jan 17;278(3):1671-9. Epub 2002 Nov 11.

49.

Activation of Rho is required for ligand-independent oncogenic signaling by a mutant epidermal growth factor receptor.

Boerner JL, Danielsen A, McManus MJ, Maihle NJ.

J Biol Chem. 2001 Feb 2;276(5):3691-5. Epub 2000 Nov 10.

50.

An oncogenic epidermal growth factor receptor signals via a p21-activated kinase-caldesmon-myosin phosphotyrosine complex.

McManus MJ, Boerner JL, Danielsen AJ, Wang Z, Matsumura F, Maihle NJ.

J Biol Chem. 2000 Nov 10;275(45):35328-34.

Supplemental Content

Loading ...
Support Center